Developed in collaboration with Eurofins laboratory partner Clinical Enterprise, LipidSeq is an NGS test for common genetic disorders of lipid metabolism
Boston Heart Diagnostics has unveiled its new genetic test LipidSeq. (Credit: Gerd Altmann from Pixabay)
US-based biotechnology company Boston Heart Diagnostics has unveiled its new genetic test, LipidSeq, for common genetic disorders of lipid metabolism.
LipidSeq is a saliva-based NGS test that identifies common genetic causes of lipid and lipoprotein disorders associated with premature cardiovascular, pancreatic, kidney, and neurological diseases.
The 23-gene test can identify several diseases, including familial forms of high cholesterol, lysosomal acid lipase deficiency and HDL deficiency states such as ApoA-I deficiency.
According to Boston Heart, the test can help understand the precise mutation and the associated disease to guide treatment decisions if the patient’s condition has a genetic component.
Early information can help educate the patient about health concerns, and persuade family members to get tested to see if they could also be at risk.
The ability to test suitable people at any age encourages the early detection and treatment of lipid and lipoprotein diseases that are impacted by genetics, said the company.
Early detection and precise treatment have a profound clinical influence on doctors, patients, and their families while also having the potential to save lives.
LipidSeq was developed in conjunction with Dr Robert A. Hegele of the London, Ontario-based Robarts Research Institute and with the assistance of Clinical Enterprise, a laboratory partner of Eurofins that handles the genetic sequencing.